Geoffrey Porges
Stock Analyst at SVB Leerink
(1.35)
# 3,611
Out of 5,090 analysts
121
Total ratings
43.37%
Success rate
-6.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $26.03 | +115.14% | 10 | Dec 15, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $25.45 | +292.93% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $718.36 | +18.33% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $63.33 | -24.21% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $329.89 | -34.52% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $226.08 | -40.29% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $20.97 | -47.54% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $121.22 | -38.13% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $49.53 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $18.55 | -46.09% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $875 → $750 | $8.42 | +8,807.36% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $455.48 | -61.58% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $35.01 | +139.93% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $48.41 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $7.49 | +714.42% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $181.30 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $26.03
Upside: +115.14%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $25.45
Upside: +292.93%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $718.36
Upside: +18.33%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $63.33
Upside: -24.21%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $329.89
Upside: -34.52%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $226.08
Upside: -40.29%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $20.97
Upside: -47.54%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $121.22
Upside: -38.13%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $49.53
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $18.55
Upside: -46.09%
Aug 10, 2021
Maintains: Outperform
Price Target: $875 → $750
Current: $8.42
Upside: +8,807.36%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $455.48
Upside: -61.58%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $35.01
Upside: +139.93%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $48.41
Upside: -
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $7.49
Upside: +714.42%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $181.30
Upside: -